Nov 2, 2021 8:30 am EDT Achieve Life Sciences Announces FDA Acceptance of IND Application for Cytisinicline’s Second Planned Indication for Nicotine E-cigarette Cessation
Oct 26, 2021 8:30 am EDT Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021
Sep 14, 2021 5:30 am EDT Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference
Aug 13, 2021 5:30 am EDT Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards
Aug 11, 2021 4:05 pm EDT Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update
Aug 11, 2021 5:30 am EDT Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen
Aug 3, 2021 5:30 am EDT Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021
Jul 22, 2021 9:35 am EDT Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use